HOME >> MEDICINE >> NEWS
Application deadline extended for new AstraZeneca neurology, psychiatry awards

Young minds program recognizes, supports future leaders

26 March 2001 -- AstraZeneca PLC announced today the extension of the application deadline to August 31, 2001 for proposal submissions for its international Young Minds in CNS Awards Program, which recognizes and promotes promising work from young physicians and investigators working in the central nervous system (CNS) therapeutic area.

AstraZeneca created the Young Minds program to help foster scientific innovation and improve treatments of CNS diseases. The peer-reviewed program will award five US $20,000 unrestricted career development awards in October 2001 to support a range of activities including research, educational efforts, travel, salary support and materials.

Through the Young Minds in CNS Awards Program, AstraZeneca intends to help develop the careers of young physicians and investigators, which ultimately will enhance effectiveness of managing CNS patients and improving their quality of life, said Ron Polinsky, M.D., Vice President, Global CNS Medical Director, AstraZeneca.

Award proposals must demonstrate how winning a Young Minds in CNS Award will develop the applicants career. The awards will be made in the following disease categories:

  • Bipolar Disorder/Mania
  • Depression
  • Migraine
  • Schizophrenia
  • Stroke (acute)

In addition to participating in the award reception at a major neurology and/or psychiatry congress in 2001, AstraZeneca will sponsor recipients to attend an international CNS-related medical meeting in the United States or Europe in 2002.

An independent steering committee representing distinguished experts in the CNS field was formed to develop the Young Minds in CNS Awards Program. As part of their commitment to this program, the steering committee will also review award applications and recommend those to be funded.

Applications are available through the AstraZeneca corporate Web site at

Contact: Janet Milton-Edwards, AstraZeneca PLC
44-16-2551-6549
Porter Novelli
25-Mar-2001


Page: 1 2

Related medicine news :

1. AIUM regional course, Doppler Imaging 2004: From Basic Applications to New Frontiers
2. NASA Uses EAI Software In Groundbreaking Medical Application
3. Komen Foundation Announces Application Deadline For 1999 National Grants
4. UW, Siemens Unveil New Panoramic Ultrasound Imaging Application Using Programmable Technology
5. As tax deadline approaches Americans say money is number one cause of stress
6. Deadline for the $10,000 Maxwell A. Pollack Award has been extended
7. Post-traumatic stress disorder increases in children with extended ICU stays after cardiac surgery
8. GP training should be extended
9. Deadline for $10,000 Maxwell A. Pollack Award has been extended!
10. Children riding in extended cab pickup trucks are at greater risk of injury
11. Biaxin XL (R) (Clarithromycin extended-release tablets) and Levaquin(R) achieve similar results for community-acquired pneumonia

Post Your Comments:
(Date:6/19/2013)... The former internist for the St. Louis Rams ... as director of prevention and wellness at St. Luke’s ... encounter with a metabolic syndrome diagnosis and a happenstance ... that he credits with sparking the paradigm-shift that has ... , “The average medical student gets 30 minutes of ...
(Date:6/19/2013)... June 19, 2013 “We are proud to ... nothing else like it in the U.S.,” says Shaun Johnson, ... an effective and inexpensive solution to a very expensive problem, ... their koi fish,” he adds. , Each package of ... to fit the shape of any water garden or pond. ...
(Date:6/19/2013)... 2013 The producers of Viewpoints TV ... Arizona. The city is located in the center of ... shed its frontier image and become an affordable city to ... fifth-largest city in the United States with a workforce strong ... residents a low cost-of-living, friendly business environment and more than ...
(Date:6/19/2013)... the incidence of cancer is many fold higher in ... an inadequate understanding on how best to treat these ... occasionally included in clinical trials, those elderly patients who ... Thus, the broader elderly patient population is not well ... Elderly Task Force is now starting a new phase ...
(Date:6/19/2013)... June 19, 2013 The Cancer Support ... promise of cancer care for the whole patient with ... the Cancer Support Community. This inaugural event, held at ... Emanuel, MD., Ph.D., recognition of Congress members who have ... voices of patients and families currently engaged in the ...
Breaking Medicine News(10 mins):Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 2Health News:Plant-based Nutrition is Key to Health Transformation of St. Luke’s Hospital Director of Prevention and Wellness 3Health News:Viewpoints TV Announces June Air Dates for Phoenix, AZ 2Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 3
(Date:6/19/2013)... June 19, 2013 Amerivet Solutions, LLC ... all branches of government from Federal to Municipal, ... their facilities to include complex metal design and ... some very complex aluminum parts for the Defense ... our capabilities to service government contracts," states ...
(Date:6/19/2013)... ZIONA, Israel , June ... announced that results from a phase I study in ... in advanced Parkinson,s patients, of ND0612, were presented at ... Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula ... delivery patch that would maintain constant levodopa plasma concentrations. ...
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- In its first major ... company dedicated to advancing development of the ... release drug therapies in patient disease populations ... the acquisition of Enzon Pharmaceutical,s PEGylation Linker ... product pipeline. Acquisition of this technology will ...
Breaking Medicine Technology:Amerivet Solutions Expands to Manufacture Complex Metal Designs 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4
Cached News: